ARS Pharmaceuticals, Inc.

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
11.11 ^USD	+6.21%		+22.22%	+102.74%

Jul. 11	Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	MT
Jul. 11	Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	MT

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index

July 30, 2024

Latest news about ARS Pharmaceuticals, Inc.

Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	Jul. 11	MT
Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	Jul. 11	MT
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000E Value Index	Jun. 30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Value Index	Jun. 30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000 Value Index	Jun. 30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2500 Value Index	Jun. 30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Microcap Value Index	Jun. 30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion	Jun. 28	MT
EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen	Jun. 28	RE
ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)	Jun. 28	CI
Ars Pharmaceuticals Insider Sold Shares Worth $913,917, According to a Recent SEC Filing	Jun. 13	MT
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	Apr. 30	CI
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	Apr. 30	CI
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18	MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18	MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	Apr. 10	MT
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	Apr. 03	MT
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy	Apr. 03	DJ
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	Apr. 03	CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6	Mar. 05	MT

Chart ARS Pharmaceuticals, Inc.

Duration

Period

More charts

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ARS Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.11 USD

Average target price

19 USD

Spread / Average Target

+71.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARS PHARMACEUTICALS, INC.	+102.74%	1.08B
MODERNA, INC.	+23.50%	47.07B
LONZA GROUP AG	+47.24%	42.06B
IQVIA HOLDINGS INC.	-5.16%	39.98B
ALNYLAM PHARMACEUTICALS, INC.	+36.37%	33.02B
CELLTRION, INC.	-7.79%	27.9B
ICON PUBLIC LIMITED COMPANY	+18.06%	27.63B
UNITED THERAPEUTICS CORPORATION	+47.29%	14.37B
MEDPACE HOLDINGS, INC.	+41.91%	13.45B
BIO-TECHNE CORPORATION	-1.02%	12.03B

Other Biotechnology & Medical Research